SCHEMBL335681

SCHEMBL335681

COc1ccc(C(N)=O)cc1OC

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.77
TSHR P16473 4/20 0.73
CYP1A2 P05177 1/20 0.73
CYP3A4 P08684 1/20 0.73
CYP2C9 P11712 1/20 0.73
CYP2C19 P33261 1/20 0.73
CA1 P00915 2/20 0.70
CA2 P00918 2/20 0.70
CA12 O43570 1/20 0.70
CA4 P22748 1/20 0.70
CA6 P23280 1/20 0.70
CA7 P43166 1/20 0.70
TPMT P51580 1/20 0.70
CA9 Q16790 1/20 0.70
CA14 Q9ULX7 1/20 0.70
ALDH1A1 P00352 2/20 0.61
GAA P10253 1/20 0.61
MAPT P10636 4/20 0.59
POLB P06746 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29415167 1.00 MAPK1 (0.77) MAPK1TSHRCYP1A2CYP3A4CYP2C9
Hydrochloric Acid SCHEMBL5154533 0.98 MAPK1 (0.74) MAPK1TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL17656092 0.92 MAPK1 (0.68) MAPK1TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL17184498 0.89 TSHR (0.73) MAPK1TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL24812339 0.88 MAPK1 (0.62) MAPK1TSHRCYP1A2CYP3A4CYP2C9
Trifluoroacetic Acid SCHEMBL4440333 0.88 MAPK1 (0.62) MAPK1TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL6944861 0.88 MAPK1 (1.00) MAPK1TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL11401711 0.86 PARP10 (0.67) MAPK1TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL29824542 0.86 KDM4E (0.61) MAPK1TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL16533679 0.86 MAPK1 (0.74) MAPK1TSHRCYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1069 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122005557-A Application of veratramine in preparing lysosome trapping inhibiting preparation and antiviral preparation 浙江大学台州研究院 2026-05-12 CN claimed
US-12575248-B2 Zinc oxide nanomaterial and preparation method thereof and semiconductor device TCL TECHNOLOGY GROUP CORPORATION (CN) 2026-03-10 US claimed
EP-4559480-A1 USE OF JUN INHIBITOR IN PREPARING MEDICAMENT FOR TREATING HEART FAILURE WITH PRESERVED EJECTION FRACTION Fuwai Hospital, Chinese Academy Of Medical Sciences And Peking Union Medical College (CN) 2025-05-28 EP claimed
CN-119708111-A Method for synthesizing cyclopamine from veratramine 华东师范大学 2025-03-28 CN claimed
CN-119667065-A Kit and method for screening 74 toxic drugs in blood 华中科技大学同济医学院附属同济医院 2025-03-21 CN claimed
CN-116375789-B Antitumor compound, preparation method thereof, pharmaceutical composition and application 北京大学第一医院 2025-03-21 CN claimed
CN-119424452-A Application of steroid alkaloid from fritillaria hupehensis in preparation of immunosuppressive drugs 中南民族大学 2025-02-14 CN claimed
WO-2024027593-A9 USE OF JUN INHIBITOR IN PREPARING MEDICAMENT FOR TREATING HEART FAILURE WITH PRESERVED EJECTION FRACTION 中国医学科学院阜外医院 2025-02-13 WO claimed
EP-4167307-B1 ZINC OXIDE NANOMATERIAL AND PREPARATION METHOD THEREFOR, AND SEMICONDUCTOR DEVICE TCL TECH GROUP CORP (CN) 2025-02-05 EP claimed
CN-119215056-A Combined anti-tumor composition, anti-tumor combination product and application thereof 北京大学第一医院 2024-12-31 CN claimed
WO-2003057183-A1 COMPOSITION FOR SKIN WHITENING LG HOUSEHOLD & HEALTHCARE CO., LTD. (KR) 2003-07-17 WO claimed
US-20030114393-A1 Use of steroidal alkaloids to reverse multidrug resistance YEDA RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) 2003-06-19 US claimed
US-20030105081-A1 Heterocyclic compounds as ligands of the GABAA receptor PFIZER INC 2003-06-05 US claimed
EP-1274445-A2 USE OF STEROIDAL ALKALOIDS TO REVERSE MULTIDRUG RESISTANCE YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) 2003-01-15 EP claimed
WO-2002028353-A2 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-04-11 WO claimed
WO-2001049279-A2 USE OF STEROIDAL ALKALOIDS TO REVERSE MULTIDRUG RESISTANCE YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2001-07-12 WO claimed
US-4970297-A CONTAINING ISOXAZOLE RING SYNTEX (U.S.A.) INC. (US) 1990-11-13 US claimed
EP-0030009-B1 NEW DERIVATIVES OF THE 9-CIS-6,6'-DIAPO-PSI,PSI-CAROTENEDIOIC ACID, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Simes S.p.A. (IT) 1983-05-11 EP claimed
US-4304935-A Production of 1-phenyl-3-cyanoureas REXOLIN CHEMICALS AB (SE) 1981-12-08 US claimed
EP-0030009-A1 New derivatives of the 9-cis-6,6'-diapo-psi,psi-carotenedioic acid, preparation thereof and pharmaceutical compositions containing same Simes S.p.A. (IT) 1981-06-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105081-A1 Heterocyclic compounds as ligands of the GABAA receptor GABRB1, GABRP, GABRA1 MAPK1 3432/4885TSHR 252/4885CYP1A2 385/4885
US-12575248-B2 Zinc oxide nanomaterial and preparation method thereof and semiconductor device ZRANB2, ZKSCAN2, SLC39A3 MAPK1 3601/4885TSHR 1082/4885CYP1A2 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.